The Federal Trade Commission will not immediately investigate pharmacy benefit managers” drug pricing practices after a deadlocked vote Feb. 17, according to Bloomberg Law..
Read the full post on Becker's Hospital Review - Healthcare News
Federal probe into PBM practices stalls after split vote
